Medicine and Dentistry
Neoplasm
100%
Hepatocellular Carcinoma
63%
Adenocarcinoma
56%
Biliary Duct Cancer
46%
Biliary Tract Cancer
42%
Cancer
37%
Overall Survival
37%
Pancreas Adenocarcinoma
36%
Malignant Neoplasm
35%
Gallbladder Cancer
33%
Chemoradiotherapy
28%
Odds Ratio
27%
Diseases
26%
Gallstone
24%
Neuroendocrine Tumor
23%
Methylation
23%
Case-Control Study
22%
Gene Mutation
22%
Metastatic Carcinoma
21%
Carcinoma
21%
Pancreaticoduodenectomy
20%
Adenoma
19%
Carcinoid
19%
Polyp
18%
Neoadjuvant Therapy
18%
Biological Marker
17%
Colorectal Carcinoma
16%
Bile Duct Cancer
15%
Ampulla of Vater
15%
Next Generation Sequencing
15%
CpG Island
15%
Protein P53
15%
Microsatellite Instability
14%
Surgery
14%
Esophageal Adenocarcinoma
13%
Esophagus
13%
Neuroendocrine Carcinoma
12%
Lymph Node Metastasis
12%
Prognostic Factor
12%
Dysplasia
12%
Clinical Trial
12%
Immunohistochemistry
12%
Extrahepatic Bile Duct
10%
Abdominal Cancer
10%
Epidermal Growth Factor Receptor
9%
Cancer Growth Factor
9%
Progression Free Survival
9%
Lymph Node
9%
Programmed Cell Death
9%
Pancreas Islet Cell Tumor
9%
Keyphrases
Hepatocellular Carcinoma
43%
Biliary Tract Cancer
42%
Pancreatic Ductal Adenocarcinoma
39%
Tumor
38%
Gallbladder Cancer
32%
Overall Survival
31%
Confidence Interval
29%
Population-based Study
28%
Shanghai China
21%
Odds Ratio
18%
Pancreaticoduodenectomy
18%
Neoadjuvant Therapy
17%
Gallstones
17%
Genetic Modification
17%
Methylation
16%
Microsatellite Instability-high (MSI-H)
16%
Metastasis
13%
Prognostic Significance
13%
Disease-free Survival
13%
CpG Island Methylation
12%
Immunohistochemistry
12%
Study in China
12%
E-cadherin
12%
Patient Survival
12%
Biliary Stone
12%
Advanced Hepatocellular Carcinoma
11%
Esophageal Adenocarcinoma
10%
Gallbladder
10%
Adenocarcinoma
10%
Lymph Node Metastasis
10%
Neoadjuvant Chemoradiotherapy (nCRT)
10%
Population-based Case-control Study
9%
Carcinoma
9%
Preoperative Chemoradiation
9%
Adenocarcinoma of the Esophagogastric Junction
9%
Carcinoid Tumor
9%
Hyperplastic Polyp
8%
Multivariate Analysis
8%
Interleukin-1β
8%
Neuroendocrine Tumor
8%
Smad3
8%
Inflammation
8%
Tumor Size
8%
Hepatocellular Carcinoma Risk
8%
Chemoradiation
7%
Liver
7%
Catenin
7%
In Cancer
7%
Overexpression
7%
Progression-free Survival
7%